Pharmacokinetics of Piperacillin-Tazobactam in Anuric Intensive Care Patients during Continuous Venovenous Hemodialysis
- Resource Type
- Authors
- J. Majcher-Peszynska; Ralf G. Mundkowski; Silke C. Mueller; Bernd Drewelow; Annette Pertschy; Heiko Hickstein; Astrid Francke; Martin Schulz
- Source
- Antimicrobial Agents and Chemotherapy. 46:1557-1560
- Subject
- Adult
Male
medicine.medical_treatment
Penicillanic Acid
Anuria
Tazobactam
Pharmacokinetics
Renal Dialysis
Intensive care
polycyclic compounds
medicine
Humans
Pharmacology (medical)
Aged
Antibacterial agent
Piperacillin
Pharmacology
business.industry
Intensive Care Units
Piperacillin, Tazobactam Drug Combination
Infectious Diseases
Anesthesia
Piperacillin/tazobactam
Drug Therapy, Combination
Hemodialysis
medicine.symptom
business
medicine.drug
- Language
- ISSN
- 1098-6596
0066-4804
The pharmacokinetics of piperacillin-tazobactam were investigated in eight anuric intensive care patients treated by continuous venovenous hemodialysis (CVVHD). The elimination half-life of piperacillin was 4.3 ± 1.2 h, and that of tazobactam was 5.6 ± 1.3 h. The contribution of CVVHD to the overall elimination was relevant (>25%) for both drugs.